Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Diabetics With Stable Ischemic Heart Disease
NCT02611596Withdrawn
- Sponsor
- Walter Reed National Military Medical Center
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in Silent myocardial ischemia (SMI) comparing Ranolazine with Placebo (2 arms). Primary endpoints: High-sensitivity cardiac troponin T at 24 weeks, N-terminal pro b-type natriuretic peptide at 24 weeks and 1 more. Planned start Nov 2016; status: withdrawn.
02
Drugs
ranolazine
03
Conditions
Silent myocardial ischemia (SMI)
Beyond the preview
Go deeper on NCT02611596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611596.